Our Pipeline
Mycovia is committed to the development of a robust pipeline of novel therapies to address the needs of patients living with overlooked medical conditions in women’s health and beyond.
Disease Indication
Pre-Clinical
Phase 1
Phase 2
Phase 3
NDA Submitted
Oteseconazole (VT-1161)
Onychomycosis
Invasive & opportunistic infections
Emerging MDR-fungi (Candida auris)
Cryptococcal meningitis (Cryptococcus neoformans)
Valley fever (Coccidioides)
Source: Mycovia Source Data on File
Worldwide clinical trials were completed for oteseconazole.
